All Stories

  1. Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes
  2. Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting